Chief Executive Officer
Tim Collard is the Chief Executive Officer of Pacific GeneTech and is responsible for the overall management and operations of the company. Tim has more than 40 years’ experience in the global pharmaceutical and biotechnology industries. In 1975 he started his career working with Connaught Laboratories supplying human vaccines to the Hong Kong government and was also involved in development of Connaught’s veterinary vaccines. In 1977 he was recruited by Califas, a China-based consultancy, where he negotiated the first Sino-US joint manufacturing contract in the Chinese healthcare industry and preliminary joint venture agreements between Squibb and the Chinese government.
In 1980 Tim joined Solvay as Far East Director for Solvay’s Biochem Products division, a joint venture with the Pasteur Institute, which developed human and agricultural biologicals. In 1987 he became General Manager, Far East, of British biopharmaceuticals company Porton International where he established marketing, distribution, and local R&D in Asia for human vaccines and biopharmaceuticals, including Porton’s botulinum toxin for treatment of neurological diseases.
In 1993, Tim served as Vice President of Lotus Healthcare Corporation, a manufacturer of oral controlled-release morphine and dihydrocodeine in China. He was responsible for business development, sourcing of Chinese pharmaceutical raw materials, and all in-licensing and technology transfer. In 1997, he established Phoenix Lifesciences to provide transactional consultancy services to the biotechnology sector in Greater China and Southeast Asia. In this consulting capacity, Tim negotiated a “first mover” supply agreements for bulk antibiotics between a Chinese producer and British pharmaceutical companies. Tim continued to work on a variety of projects with local and multinational companies including AstraZeneca, Authentix, Aventis, bioMérieux, Proctor & Gamble, SciClone, and Xenova.
Tim holds a BS in biology from Bristol University in the United Kingdom.
Executive Chairman and Director, Finance
Louis Bowen, MBA, is the Executive Chairman and Director of Finance of Pacific GeneTech Limited which he co-founded in 2009. He also currently serves as the Chairman and CEO of Asia Capital Management Limited, a private investment banking company based in Hong Kong that he founded in 1994.
Previously, he served as Managing Director of Arral and Partners Limited, one of the first private investment companies in Asia. Louis started his career with Citigroup in New York, before relocating to Hong Kong to establish the Citigroup corporate finance activities in Asia. Louis has overseen many investments and acquisitions in Asia across a range of industries including pharmaceuticals, primary care services, and medical diagnostics.
Louis has served on the boards of a number of companies during his professional career and currently serves on the Advisory Council of the Hong Kong University of Science and Technology Business School, The Dean’s Executive Advisory Board of the Walton School of Business at the University of Arkansas, the Board of Governors of the Wharton Alumni Association of Hong Kong and the Board of Advisors of the Arkansas World Trade Center.
He was a co-founder of the Hong Kong Venture Capital Association. He is a member of the Hong Kong Forum, an Asian regional think-tank affiliated with the US Council on Foreign Relations, and has been a member of the Hong Kong Chapter of the YPO/WPO organization.
Louis holds an MBA in Finance from the Wharton School and has a BA in Economics from the University of Arkansas.
Director, Business Development
Cindy Tsang, MBA, has over 15 years of broad international experience in corporate strategy and advisory, compliance consulting, and scientific R&D for multinational pharmaceutical corporations, major investment banks, consulting firms, and early stage companies.
Cindy joined PGT in 2013 from an advisory firm she founded where she assisted early stage healthcare companies in medical devices, diagnostics and healthcare IT with business planning, fundraising, and growth strategies development. Cindy held management positions as an Assistant Director in the quality and risk management group at Ernst & Young and previously an Associate at Morgan Stanley in Hong Kong. She also had prior experience as an investment banking analyst at a boutique Mergers and Acquisitions advisory firm in Chicago where she led commercial due diligence on potential investments for a life sciences venture fund.
Cindy began her career as a research scientist at Abbott Laboratories’ Pharmaceutical R&D division in Abbott Park, Illinois. She spearheaded a membrane protein purification project to support the use of structural biology in drug discovery efforts. Her work has been published in scientific journals.
Cindy holds an MBA in Finance from the University of Cambridge and a BS in Biochemistry from Seattle University.
Senior Operations Advisor
Bruce Smith serves as a Senior Operations Advisor for Pacific GeneTech, assisting in the establishment and commissioning of the PGT offices, labs and production facility in Northwest Arkansas. Prior to PGT Mr. Smith was Chief Operating Office of Safe Foods Corporation from 2001 to 2017 where he oversaw the delivery technology development, equipment/system buildout and installation, process improvement and many other operational functions. He also managed the building of the Safe Foods International Headquarters, manufacturing and R&D facility in North Little Rock Arkansas until his retirement in 2019.
Prior to Safe Foods, he had a 22 year career with Entergy Corporation, serving as an Engineer, Power Plant Manager, Industrial and Community Development Manager, Division Manager, Marketing Director and finally Managing Director for Transition Projects. He began his career as an Industrial Engineer with Timex Corporation.
Smith obtained a Bachelor of Science degree in Industrial Engineering and a Master of Science degree in Operations Management from the University of Arkansas. He has also attended Executive Education Programs at Columbia University, the University of Michigan and the Wharton School at the University of Pennsylvania. He has completed numerous other programs in total quality management, performance management, sales leadership and general management.
Dr. Thomas D. Overbay
Director, U.S. Operations
Dr Overbay brings over 25 years of experience in the veterinary pharmaceutical industry. Previously, he has served in senior business development roles for a major animal health company, contract services provider, and start-up animal health companies in the US and internationally.He is one of the founders of Expedite Animal Health which is a company formed to assist with the commercialisation of products in the veterinary industry.
In addition to business development, Dr Overbay’s background of veterinary practice, technical services, and sales management provides him with a unique perspective of the scientific, financial, and legal aspects of innovative technologies. Dr Overbay has successfully brought to market a number of products arising from universities, government agencies, human hospitals, human and veterinary health start-up companies, and multinational pharmaceutical and chemical companies.
Dr Overbay holds a degree in Veterinary Medicine from the Virginia-Maryland Regional College of Veterinary Medicine.
Dr. Anna Obolensky
Director, Translational Research
Dr Obolensky is a microbiologist and immunologist with experience in pharmaceuticals, research institutions and private equity. She has extensive experience in intellectual property management, commercialisation, and research.
She started her career at Porton International, which commercialised drugs and vaccines originating from the British government’s Centre for Applied Microbiology and Research at Porton Down. Dr Obolensky established the company’s Hong Kong office to oversee clinical development and trials in Asia for novel products.
Following her work at Porton, Dr Obolensky completed a PhD in immunology. She then worked as an independent consultant advising companies and institutions on ways to evaluate, protect, and maximise their IP for commercialisation.
Later, Dr Obolensky served as Head of External Sciences for H2O Venture Partners, a private equity firm focused on early stage technologies. Since 2011, Dr Obolensky has worked as a consultant for the British Heart Foundation responsible for auditing BHF-funded scientists across 14 British universities.
Dr. Obolensky holds a PhD from Keble College, University of Oxford. She is a Fellow of the Royal Society of Medicine and a Member of British Society of Immunology.